Mycophenolic acid
Mycophenolic, Myfortic (mycophenolic acid) is a small molecule pharmaceutical. Mycophenolic acid was first approved as Myfortic on 2004-02-27. It is used to treat graft vs host disease and psoriasis in the USA. The pharmaceutical is active against inosine-5'-monophosphate dehydrogenase 1 and inosine-5'-monophosphate dehydrogenase 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| skin and connective tissue diseases | D017437 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Mycophenolate, Myfortic (discontinued: Mycophenolate)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cellcept | New Drug Application | 2026-08-05 |
| mycophenolate mofetil | ANDA | 2026-09-20 |
| mycophenolic acid | ANDA | 2026-09-09 |
| myfortic | New Drug Application | 2026-07-29 |
| myhibbin | New Drug Application | 2026-04-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| psoriasis | EFO_0000676 | D011565 | L40 |
| graft vs host disease | — | D006086 | D89.81 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J7518 | Mycophenolic acid, oral, 180 mg |
Clinical
Clinical Trials
1388 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney transplantation | D016030 | — | — | 4 | 9 | 27 | 46 | 3 | 86 |
| Liver transplantation | D016031 | EFO_0010682 | — | — | 1 | 6 | 5 | 2 | 14 |
| Immunosuppression therapy | D007165 | — | — | — | — | — | 4 | 4 | 8 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | 1 | 1 | 3 | 2 | 7 |
| Heart transplantation | D016027 | EFO_0010673 | — | — | — | 1 | 6 | — | 7 |
| Hepatitis c | D006526 | — | B19.2 | — | 1 | 2 | 2 | 1 | 6 |
| Renal insufficiency | D051437 | — | N19 | — | — | 2 | 2 | 1 | 5 |
| Graft vs host disease | D006086 | — | D89.81 | — | — | 3 | 2 | — | 5 |
| Graft rejection | D006084 | — | — | — | 1 | 2 | 1 | — | 4 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | 1 | 1 | 3 |
Show 25 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psychology rejection | D012059 | — | — | 2 | 3 | 2 | — | 1 | 6 |
| Lung transplantation | D016040 | — | — | — | — | 1 | — | 1 | 2 |
| Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | — | — | 1 | — | 1 | 2 |
| Syndrome | D013577 | — | — | 1 | — | 1 | — | — | 2 |
| Organ transplantation | D016377 | — | — | — | — | 1 | — | — | 1 |
| Death | D003643 | PATO_0001422 | — | — | — | 1 | — | — | 1 |
| Bronchiolitis obliterans | D001989 | EFO_0007183 | J44.81 | — | — | 1 | — | — | 1 |
| Opportunistic infections | D009894 | — | — | — | — | 1 | — | — | 1 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 1 | — | — | 1 |
| Nephrotic syndrome | D009404 | EFO_0004255 | N04 | — | — | 1 | — | — | 1 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Virus diseases | D014777 | — | B34 | — | 2 | — | — | — | 2 |
| Lupus nephritis | D008181 | EFO_0005761 | — | — | 1 | — | — | 1 | 2 |
| Epstein-barr virus infections | D020031 | EFO_0000769 | — | — | 1 | — | — | — | 1 |
| Proteus infections | D011512 | EFO_1001130 | — | — | 1 | — | — | — | 1 |
| Patient compliance | D010349 | — | — | — | 1 | — | — | — | 1 |
| Myositis | D009220 | EFO_0000783 | G72.49 | — | 1 | — | — | — | 1 |
| Dermatomyositis | D003882 | EFO_0000398 | M33 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sjogren's syndrome | D012859 | EFO_0000699 | M35.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 1 | 1 |
| End stage liver disease | D058625 | EFO_1001311 | K72.1 | — | — | — | — | 1 | 1 |
| Uveitis | D014605 | EFO_1001231 | H20.9 | — | — | — | — | 1 | 1 |
| Hepacivirus | D016174 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mycophenolic acid |
| INN | mycophenolic acid |
| Description | Mycophenolic acid is a member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases. It has a role as an antineoplastic agent, an antimicrobial agent, an EC 1.1.1.205 (IMP dehydrogenase) inhibitor, an immunosuppressive agent, a mycotoxin, a Penicillium metabolite, an environmental contaminant, a xenobiotic and an anticoronaviral agent. It is a gamma-lactone, a member of phenols, a monocarboxylic acid and a member of 2-benzofurans. It is functionally related to a hex-4-enoic acid. It is a conjugate acid of a mycophenolate. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)O)C(=O)OC2 |
Identifiers
| PDB | — |
| CAS-ID | 24280-93-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL866 |
| ChEBI ID | 168396 |
| PubChem CID | 446541 |
| DrugBank | DB01024 |
| UNII ID | HU9DX48N0T (ChemIDplus, GSRS) |
Target
Agency Approved
IMPDH1
IMPDH1
Organism
Homo sapiens
Gene name
IMPDH1
Gene synonyms
IMPD1
NCBI Gene ID
Protein name
inosine-5'-monophosphate dehydrogenase 1
Protein synonyms
IMP (inosine 5'-monophosphate) dehydrogenase 1, IMP (inosine monophosphate) dehydrogenase 1, IMPD 1, IMPDH 1, IMPDH-I
Uniprot ID
Mouse ortholog
Impdh1 (23917)
inosine-5'-monophosphate dehydrogenase 1 (P50096)
Alternate
No data
Variants
No data
Financial
Estimated US medical usage
Mycophenolic acid
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cellcept, Mycophenolate mofetil, Mycophenolic acid, Myfortic, Myhibbin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
136,445 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use